BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma

Celeste Lebbé1, Alexandre How-Kit, Maxime Battistella

  • 1aAP-HP, Department of Dermatology, Saint-Louis Hospital bParis-Diderot University, Sorbonne Paris Cite cINSERM U976 dLaboratory for Functional Genomics, Jean Dausset Fondation - CEPH eAP-HP, Pathology Laboratory, Saint-Louis Hospital, INSERM UMR_S 1165 fAP-HP, Saint-Louis Hospital, Pharmacology-Genetic Laboratory gDepartment of Biostatistics and Medical Data Processing, INSERM-U717 hLaboratory for Epigenetics and Environment, Genotyping National Center, CEA, Genomic Institute iINSERM UMR-S 940, Paris, France.

Melanoma Research
|June 17, 2014
PubMed
Abstract

No abstract available in PubMed .